
Metacrine MTCR
Quarterly report 2022-Q3
added 11-14-2022
Metacrine Accounts Payables 2011-2026 | MTCR
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Metacrine
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 368 K | 334 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 368 K | 334 K | 351 K |
Quarterly Accounts Payables Metacrine
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 691 K | 503 K | 264 K | 368 K | 323 K | 261 K | 325 K | 334 K | 334 K | 334 K | 334 K | 239 K | 239 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 691 K | 239 K | 350 K |
Accounts Payables of other stocks in the Biotechnology industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MannKind Corporation
MNKD
|
9.03 M | $ 3.56 | 24.48 % | $ 1.09 B | ||
|
AgeX Therapeutics
AGE
|
1.93 M | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
570 M | - | - | $ 866 M | ||
|
Bio-Techne Corporation
TECH
|
25.3 M | $ 47.41 | -16.36 % | $ 7.47 B | ||
|
United Therapeutics Corporation
UTHR
|
7.1 M | $ 596.76 | 4.29 % | $ 26.4 B | ||
|
Athira Pharma
ATHA
|
4.59 M | - | - | $ 269 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
3.38 M | - | - | $ 231 M | ||
|
INmune Bio
INMB
|
199 K | $ 1.52 | -1.3 % | $ 37.6 M | ||
|
Exelixis
EXEL
|
29.6 M | $ 48.7 | 9.64 % | $ 13.2 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
16.2 M | $ 21.48 | -3.89 % | $ 3.56 B | ||
|
Fortress Biotech
FBIO
|
14.2 M | - | - | $ 71.1 M | ||
|
Advaxis
ADXS
|
6.08 M | - | -9.65 % | $ 45.9 M | ||
|
Esperion Therapeutics
ESPR
|
65.1 M | $ 3.15 | 1.19 % | $ 655 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
561 K | - | - | $ 5.51 M | ||
|
Aeglea BioTherapeutics
AGLE
|
677 K | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.91 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
611 K | - | 1.93 % | $ 17.4 M | ||
|
Akero Therapeutics
AKRO
|
9.03 M | - | - | $ 3.67 B | ||
|
Aptose Biosciences
APTO
|
2.91 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
724 K | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
1.28 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
6.52 M | - | -0.23 % | $ 916 M | ||
|
Allakos
ALLK
|
1.76 M | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
1.28 M | - | 4.14 % | $ 49.1 M | ||
|
Arcutis Biotherapeutics
ARQT
|
12.5 M | $ 24.17 | 3.2 % | $ 3.08 B | ||
|
Allena Pharmaceuticals
ALNA
|
1.03 M | - | 3.16 % | $ 1.9 M | ||
|
Ampio Pharmaceuticals
AMPE
|
750 K | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
1.58 M | - | - | $ 10.1 M | ||
|
Alpine Immune Sciences
ALPN
|
4.29 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
3.98 M | - | 10.36 % | $ 9.8 M | ||
|
Applied Therapeutics
APLT
|
1.74 M | - | - | $ 8.42 M | ||
|
Aravive
ARAV
|
8.76 M | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
2.31 M | - | 17.91 % | $ 11.1 M | ||
|
CRISPR Therapeutics AG
CRSP
|
11.1 M | $ 55.08 | 5.15 % | $ 4.95 B | ||
|
Avenue Therapeutics
ATXI
|
78 K | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
3.08 M | $ 1.7 | 3.66 % | $ 452 M | ||
|
AVROBIO
AVRO
|
27 K | - | 1083.1 % | $ 745 M | ||
|
Ayala Pharmaceuticals
AYLA
|
4.08 M | - | - | $ 7.46 M |